NERV Minerva Neurosciences, Inc.

Nasdaq minervaneurosciences.com


$ 4.61 $ 0.00 (0 %)    

Wednesday, 29-Oct-2025 05:37:07 EDT
QQQ $ 634.91 $ 0.00 (0 %)
DIA $ 475.95 $ 0.00 (0 %)
SPY $ 688.09 $ 0.00 (0 %)
TLT $ 91.98 $ 0.00 (0 %)
GLD $ 370.56 $ 0.00 (0 %)
$ 4.6
$ 4.46
$ 4.54 x 10
$ 4.75 x 50
-- - --
$ 1.15 - $ 12.46
430,415
na
32.17M
$ 0.29
$ 2.86
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 02-25-2025 12-31-2024 10-K
4 11-05-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-01-2024 03-31-2024 10-Q
7 02-22-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-01-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-08-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-02-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
19 03-08-2021 12-31-2020 10-K
20 11-02-2020 09-30-2020 10-Q
21 08-03-2020 06-30-2020 10-Q
22 05-04-2020 03-31-2020 10-Q
23 03-09-2020 12-31-2019 10-K
24 11-04-2019 09-30-2019 10-Q
25 08-05-2019 06-30-2019 10-Q
26 05-06-2019 03-31-2019 10-Q
27 03-12-2019 12-31-2018 10-K
28 11-05-2018 09-30-2018 10-Q
29 08-02-2018 06-30-2018 10-Q
30 05-03-2018 03-31-2018 10-Q
31 03-12-2018 12-31-2017 10-K
32 11-06-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 03-13-2017 12-31-2016 10-K
36 11-03-2016 09-30-2016 10-Q
37 08-04-2016 06-30-2016 10-Q
38 05-03-2016 03-31-2016 10-Q
39 03-14-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 minerva-stock-rises-after-securing-200m-for-schizophrenia-drug-trial

Minerva Neurosciences Inc (NASDAQ:NERV) shares are climbing Tuesday after the company announced up to $200 million in funding t...

 minerva-neurosciences-q2-eps-043-beats-090-estimate

Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of...

 hc-wainwright--co-reiterates-neutral-on-minerva-neurosciences-maintains-5-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Minerva Neurosciences (NASDAQ:NERV) with a Neutral and maintains $5 ...

 minerva-neurosciences-q4-2024-gaap-eps-056-beats-105-estimate-cash-cash-equivalents-and-restricted-cash-at-december-31-2024-were-approximately-215m

Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of...

 hc-wainwright--co-reiterates-neutral-on-minerva-neurosciences-maintains-5-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Minerva Neurosciences (NASDAQ:NERV) with a Neutral and maintains $5 ...

 minerva-neurosciences-q3-2024-gaap-eps-297-may-not-be-comparable-to-101-estimate

Minerva Neurosciences (NASDAQ:NERV) reported quarterly earnings of $2.97 per share which may not be comparable to analyst conse...

 hc-wainwright--co-maintains-neutral-on-minerva-neurosciences-lowers-price-target-to-5

HC Wainwright & Co. analyst Douglas Tsao maintains Minerva Neurosciences (NASDAQ:NERV) with a Neutral and lowers the pri...

 hc-wainwright--co-maintains-neutral-on-minerva-neurosciences-lowers-price-target-to-7

HC Wainwright & Co. analyst Douglas Tsao maintains Minerva Neurosciences (NASDAQ:NERV) with a Neutral and lowers the pri...

 minerva-neurosciences-q1-2024-gaap-eps-113-beats-120-estimate-cash-cash-equivalents-and-restricted-cash-of-349m

Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION